Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 all comers meta-analysis

LIFESAVER
  NCT04374526		 RCTconvalescent plasma treatmentstandard of careCOVID 19 all comerslow
4/8 inconclusive
    Cai -FAVIPIRAVIR
          ChiCTR2000029600    		 NRainterferoninterferonCOVID 19 all comersNA
    		35/45 uncontrolled
    • [uncontrolled] Chest CT improvement (day 14): 91.4% (32/35)
    Cai -FAVIPIRAVIR
          ChiCTR2000029600    		 NRainterferonlopinavir/ritonavirCOVID 19 all comersNA
    		35/45 uncontrolled
    • [uncontrolled] Chest CT improvement (day 14): 91.4% (32/35)

    PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
    Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

     

    - About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons